Elevance Health's ELV stock drops 3.41% with $1.43 billion in trading volume, placing 93rd, as CMS penalties and an ongoing legal investigation dampen investor sentiment

Market Overview

On March 3, 2026, shares of Elevance Health (ELV) dropped by 3.41%, with trading volumes reaching $1.43 billion, placing the stock 93rd in market activity for the day. This decline signals increased investor wariness following recent company announcements and regulatory actions.

Main Factors Influencing the Stock

The significant decrease in Elevance’s share price is largely due to the Centers for Medicare & Medicaid Services (CMS) imposing intermediate sanctions on the company’s Medicare Advantage-Prescription Drug plans. On February 27, 2026, Elevance revealed through a Form 8-K filing that CMS intended to halt new enrollments and restrict certain communications with Medicare beneficiaries starting March 31, 2026. These penalties stem from allegations that Elevance failed to comply with risk adjustment data submission rules, including using flash drives instead of CMS-approved electronic methods for submitting diagnosis codes over the past seven years. CMS described the violations as “substantial and persistent,” raising concerns about potential disruptions to Elevance’s Medicare Advantage revenue and its competitive standing in the market.

Adding to the regulatory challenges, the law firm Johnson Fistel, PLLP, which specializes in shareholder rights, has launched an investigation into Elevance and its leadership for possible breaches of federal securities laws. The investigation focuses on whether Elevance sufficiently disclosed compliance risks and the financial consequences of the CMS sanctions. Such legal scrutiny often undermines investor trust, as it brings attention to governance issues and possible legal exposure. Analysts warn that if the enrollment freeze continues, Elevance could lose further market share in Medicare Advantage, intensifying downward pressure on the stock.

The CMS actions also raise broader financial risks for Elevance. The Medicare Advantage segment is a major source of revenue, and the enrollment suspension could accelerate member losses. While Elevance had already reported a 14% reduction in membership for 2026 due to strategic withdrawals from unprofitable regions, the new sanctions could deepen these losses. According to Leerink analysts, the company’s reputation may suffer further from regulatory scrutiny, discouraging brokers and agents from recommending Elevance’s plans and complicating future growth. Additionally, Elevance may face demands to repay funds received for unsupported diagnosis codes, which could negatively impact its cash flow.

Elevance’s efforts to address the crisis have produced mixed results. The company has stated that it is cooperating with CMS and has updated its data submission processes since April 2023 in response to regulatory feedback. However, CMS reported ongoing noncompliance as recently as October 2025, casting doubt on the effectiveness of these changes. Elevance also requested that CMS forgo repayment demands for unsupported diagnosis codes, but the agency rejected this request, citing federal regulations. This ongoing conflict highlights the regulatory hurdles Elevance must overcome to maintain its Medicare Advantage operations, with a court decision on the sanctions expected by March 31, 2026.

The recent stock decline also mirrors broader trends in the healthcare sector. Although Elevance’s CarelonRx and Carelon Services divisions remain relatively stable, the industry as a whole faces increased scrutiny over risk adjustment practices. Regulatory reforms under the Biden administration have already pressured major insurers like UnitedHealth Group, and proposals from the Trump administration suggest continued oversight. Elevance’s challenges underscore the vulnerability of Medicare Advantage business models that depend on accurate data reporting, making investors more cautious about compliance risks.

In conclusion, Elevance’s recent stock performance is shaped by a combination of regulatory sanctions, legal investigations, and operational weaknesses. The CMS penalties and ongoing securities probe have shaken investor confidence, while persistent concerns about the profitability and governance of the Medicare Advantage business remain. The company’s ability to resolve these issues before the March 31 deadline will be crucial in determining its stock’s future direction, with further declines possible if sanctions are upheld or legal actions intensify.